Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774435 · ClinicalTrials.gov registry record · Phase 1
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
A Phase 1 study of Schizophrenia, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT01774435 is a Phase 1 study of Schizophrenia that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 35 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01774435, a Phase 1 study of Schizophrenia, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an study evaluating the safety, tolerability, and PK of EN3342 in implantation durations of 6 months.
Conditions Studied
Interventions
- DRUG EN3342
Study Locations (1)
New Jersey
- CRI Lifetree - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774435
The ClinicalTrials.gov registry entry for NCT01774435 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (84% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which EN3342 is the first listed.
NCT01774435 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01774435 about?
NCT01774435 is a clinical study titled "Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant". This is an study evaluating the safety, tolerability, and PK of EN3342 in implantation durations of 6 months.
What is the current status of trial NCT01774435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2012-10. Estimated completion is 2013-10.
What conditions does trial NCT01774435 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01774435?
The interventions under investigation include: EN3342 (DRUG).
Who is sponsoring clinical trial NCT01774435?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01774435 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.